This trial aims to evaluate the safety and effectiveness of using a product made umbilical cord blood in Stroke. The trial is being conducted at four major hospital centres in Hong Kong by the China Spinal Injury Network and StemCyte Inc. The trial proposes to recruit 12 subjects who have had an ischaemic stroke (cardiovascular accident). Participants will be randomly divided into a group receiving only conventional treatment for stroke (control group); and a group receiving an injection of a proprietary product made from donate umbilical cord blood, in addition to the conventional treatment (experimental group). Participants will be monitored for complications and for changes in clinical condition. The trial commenced in October 2013 and is expected to be completed by March 2016.